Comparative Effects of Aminopterin, Cortisone and Acth in Experimental Formaldehyde Arthritis and Psoriatic Arthritis*

Gubner, Richard; Coté, Lucille; Hughes, Jeanne; Oleson, J. J.; Ruegsegger, James M.; Williams, James H.

doi:10.1038/jid.1952.100

Cited by 10 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Madonia (1952) suggested that methyl thiouracil acted via the pituitary/adrenal axis in suppressing the development of formalin arthritis. Gubner, Cote, Hughes, Oleson, Ruegsegger, and Williams (1952) confirmed the benefits of cortisone and of ACTH. Bacchus (1952) found that ascorbic acid did not influence the formalin changes in adrenalectomized rats, suggesting that ascorbic acid acted on the intact adult animal by influencing the adrenal cortical hormones.…”

Section: Experimental Production Of Arthritismentioning

confidence: 56%

The Experimental Production of Arthritis: A Review

Gardner¹

1960

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Section: Experimental Production Of Arthritismentioning

confidence: 56%

The Experimental Production of Arthritis: A Review

Gardner¹

1960

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…The rationale for the introduction of MTX for the treatment of RA was assumed on its capacity to inhibit inflammatory and proliferative response of connective tissue. The closely related antifolate aminopterin, a synthetic derivative of pterin, was shown to suppress exudative and proliferative changes in experimental formaldehyde arthritis [21]. Aminopterin was gradually replaced by MTX due to its less toxic nature and the first documented clinical use of MTX for the treatment of RA was in 1951 [22].…”

Section: Historymentioning

confidence: 99%

Methotrexate an Old Drug with New Tricks

Bedoui

Guillot

Sélambarom

et al. 2019

IJMS

302

192

View full text Add to dashboard Cite

Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug in the treatment of rheumatoid arthritis (RA). Despite the development of numerous new targeted therapies, MTX remains the backbone of RA therapy due to its potent efficacy and tolerability. There has been also a growing interest in the use of MTX in the treatment of chronic viral mediated arthritis. Many viruses—including old world alphaviruses, Parvovirus B19, hepatitis B/C virus, and human immunodeficiency virus—have been associated with arthritogenic diseases and reminiscent of RA. MTX may provide benefits although with the potential risk of attenuating patients’ immune surveillance capacities. In this review, we describe the emerging mechanisms of action of MTX as an anti-inflammatory drug and complementing its well-established immunomodulatory activity. The mechanisms involve adenosine signaling modulation, alteration of cytokine networks, generation of reactive oxygen species and HMGB1 alarmin suppression. We also provide a comprehensive understanding of the mechanisms of MTX toxic effects. Lastly, we discussed the efficacy, as well as the safety, of MTX used in the management of viral-related rheumatic syndromes.

show abstract

“…While part of Acthar Gel’s efficacy is mediated through the production of steroids from the adrenal cortex, the non-steroidogenic anti-inflammatory effects via MCR activation are the most interesting. Studies in animal models of inflammation suggest responses to ACTH in the absence of adrenal steroid production 12 . Additionally, Bomback et al 18 have demonstrated previously that cortisol levels after administration of Acthar Gel were within normal limits, supporting a limited contribution for cortisol in responses to Acthar Gel, at least in this population of patients on long-term prednisone therapy.…”

Section: Discussionmentioning

confidence: 99%

“…The MC1R-selective agonists inhibited tumor necrosis factor α (TNF-α)-induced activation of NF-κB and down-regulated expression and secretion of endothelial cell selectin, vascular cell adhesion molecule, and intercellular adhesion molecule in human dermal vascular endothelial cells treated with TNF-α 4 , 11 . In a study with adrenalectomized rats, Acthar Gel decreased experimental arthritis, indicating a steroid-independent action 12 .…”

Section: Introductionmentioning

confidence: 96%

Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.

Golubovsky

Hui-Yuen

et al. 2016

F1000Res

View full text Add to dashboard Cite

Objectives: Acthar Gel is a long-acting formulation of adrenocorticotropic hormone (ACTH) with anti-inflammatory effects thought to be mediated in part through melanocortin receptor activation. This study was initiated to understand the role of Acthar Gel in SLE treatment in rheumatology practices. Methods: This is a retrospective case series of nine adult female patients treated with Acthar Gel for at least six months at five academic centers. Treating physicians completed a one-page questionnaire on lupus medications, disease activity, and outcomes. Clinical response was defined using SLEDAI 2K and improvement in the clinical manifestation(s) being treated. Results: The most common clinical SLE manifestations/indications requiring therapy with Acthar Gel were arthritis, rash, and inability to taper corticosteroids. The mean SLEDAI 2K score at baseline was 5.8 ± 5.0 (range 0-16). Six patients were concomitantly treated with corticosteroids (mean dose 18.3mg/day). All patients were on background SLE medications including immunosuppressives. Seven of nine patients had an overall improvement, with a decrease in SLEDAI 2K from 5.8 ± 5.0 at baseline to 3.5 ± 2.7 (range 0-8); four of five patients had improvement or resolution in arthritis, and one of two patients had resolution of inflammatory rash. Four patients discontinued corticosteroids and one patient tapered below 50% of the initial dose by 3 months of treatment with Acthar Gel. No adverse events were reported. Conclusions: This study suggests a role for Acthar Gel as an alternative to corticosteroids in the treatment of SLE. Acthar Gel appears to be safe and well-tolerated after 6 months of treatment, with a significant reduction in disease activity.

show abstract

Comparative Effects of Aminopterin, Cortisone and Acth in Experimental Formaldehyde Arthritis and Psoriatic Arthritis*

Cited by 10 publications

References 13 publications

The Experimental Production of Arthritis: A Review

The Experimental Production of Arthritis: A Review

Methotrexate an Old Drug with New Tricks

Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.

Contact Info

Product

Resources

About